Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
BMC Complement Med Ther ; 21(1): 269, 2021 Oct 26.
Artículo en Inglés | MEDLINE | ID: mdl-34702240

RESUMEN

BACKGROUND: The present study extensively aimed to evaluate the underlying mechanism of the immunomodulatory and anti-inflammatory effects of Phellinus linteus mycelium (PLM). METHODS: To assess whether PLM influences the production of markers related to inflammation, Lipopolysaccharide (LPS)-stimulated RAW264.7 cells were treated with PLM (50, 100, 200, and 500 µg/mL). Splenocyte, thymus, peritoneal exudate cells (PEC), and peripheral blood mononuclear cells (PBMC) were isolated from the Balb/c mice treated with Korean red ginseng or PLM once a day for 5 weeks. Moreover, all mice except normal mice were stimulated with 10% proteose peptone (PP) treated 3 days before the sacrifice and 2% starch treated 2 days before the sacrifice. Subsequently, the cytotropic substance was evaluated by using flow cytometry analysis and ELISA assay. RESULTS: PLM200 treatment significantly suppressed the production of nitric oxide (NO) and prostaglandin E2 (PGE2) and inhibited the release of proinflammatory cytokines such as interleukin (IL)-6, IL-1ß, and tumor necrosis factor (TNF)-α dose-dependently in the LPS-stimulated RAW264.7 cells. PLM200 supplementation showed a significant increase in IL-2, IL-12, and interferon (IFN)-γ production and upregulated the ratio of IFN-γ (T-helper type 1, Th1) to IL-4 (T-helper type 2, Th2) in splenocytes. After PLM200 treatment, the significant elevation of CD4+CD25+, CD4+&CD8+, and CD4+CD69+ treatment were detected in thymus. Moreover, CD4+ and CD4+CD69+ in PBMC and CD69+ in PEC were also shown in a significant increase. CONCLUSIONS: Taken together, these results showed an immunomodulatory effect of PLM about an elevated INF-γ/IL4 ratio, as an index of Th1/Th2, as well as the anti-inflammatory effect in the LPS-stimulated RAW264.7 cells. Therefore, our findings demonstrate that PLM possesses immunostimulatory and anti-inflammatory effects.


Asunto(s)
Antiinflamatorios/farmacología , Agentes Inmunomoduladores/farmacología , Extractos Vegetales/farmacología , Animales , Australia , Lipopolisacáridos , Masculino , Ratones , Ratones Endogámicos BALB C , Phellinus , Células RAW 264.7/efectos de los fármacos , República de Corea
2.
Artículo en Inglés | MEDLINE | ID: mdl-32908566

RESUMEN

OBJECTIVE: The aim of this study was to identify the protective effects of Phellinus linteus mycelium (PLM) and its possible mechanisms in a model of monosodium iodoacetate- (MIA-) induced osteoarthritis (OA). METHODS: Intra-articular injection of MIA was injected to 50 µL with 80 mg/mL using a 0.3 mL insulin syringe into the right knee joint. Changes in hindpaw weight-bearing distribution between the right (osteoarthritic) and left (contralateral control) legs were used as an index of joint discomfort. PLM (50, 100, and 200 mg/kg body weight) was orally administered once daily for 14 days from day 7 after MIA treatment. And then, various factors associated with inflammatory response and cartilage degeneration in cartilage tissues detected by western blotting. RESULTS: PLM treatment showed a concentration-dependent elevation in change in hindpaw weight-bearing distribution (HWBD). PLM200 demonstrated the capacity to significantly increase HWBD, indicating that the change in weight-bearing distribution means the reduction of spontaneous pain. Our results indicate that PLM suppressed the inflammatory factors via NF-κB signaling pathway induced by p38 phosporlyation. Moreover, PLM200 exhibited a significant reduction of ROS produced by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. PLM100 and PLM200 inhibited the levels of matrix metalloproteinase (MMP)-1, one of proteinase that degrades extracellular matrix (ECM). CONCLUSIONS: Taken together, our results indicated that PLM has a strong chondroprotective effect through the suppression both ROS production and inflammation.

3.
Biomed Pharmacother ; 125: 110018, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32092828

RESUMEN

INTRODUCTION: In recent decades, fine-dust particulate matter (FM) has become a potential health hazard, causing various pathological respiratory disorders around the world. Inflammation induced by FM is regarded as a major cause of respiratory disorder in humans. The purpose of this study was to evaluate the therapeutic efficacy of Shibashin Misena®, a functional food composed of various bioactive ingredients, on FM-induced respiratory disorders in mice. MATERIALS AND METHODS: Briefly, 40 mice were divided equally into four groups: normal controls (NC); FM-induced control group (FC); FM group treated with Shibashin Misena® 0.1 mL/head/day (FM0.1); FM group treated with Shibashin Misena® 0.2 mL/head/day (FM0.2). RESULTS: FM significantly induced TNF-α, IL-17A, IL-1ß, and TGF-ß in bronchoalveolar lavage fluid (BALF) collected from the FM mice. Compared with FC, Shibashin Misena® decreased TNF-α, IL-17A, and IL-1ß levels in BALF, and histopathologic evaluations revealed that Shibashin Misena® treatment significantly reduced inflammatory-cell infiltration and fibrosis related collagen deposition in lung tissue. CONCLUSION: This study demonstrated that Shibashin Misena® decreased FM-induced inflammation and fibrosis in lung tissue. Thus, Shibashin Misena® could be an effective supplement to prevent or improve FM-induced pulmonary disorders.


Asunto(s)
Polvo , Alimentos Funcionales , Enfermedades Pulmonares/dietoterapia , Enfermedades Pulmonares/etiología , Material Particulado/efectos adversos , Animales , Antiinflamatorios/administración & dosificación , Biomarcadores , Citocinas/metabolismo , Manejo de la Enfermedad , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Inmunohistoquímica , Mediadores de Inflamación/metabolismo , Enfermedades Pulmonares/metabolismo , Enfermedades Pulmonares/patología , Ratones , Fibrosis Pulmonar/tratamiento farmacológico , Fibrosis Pulmonar/etiología , Fibrosis Pulmonar/metabolismo , Fibrosis Pulmonar/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA